Replies to post #399888 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

Why is this not criminal risk to an innocent patient?

STORY AT-A-GLANCE
The U.S. Food and Drug Administration (FDA) granted accelerated approval for the Alzheimer’s disease drug lecanemab (Leqembi)
The drug, a monoclonal antibody, binds to amyloid beta in the brain
The most common reactions included amyloid-related imaging abnormalities, or ARIA, which involves swelling and bleeding in the brain that can be life-threatening. During the trial, ARIA occurred more often in people with the APOE4 gene, which is considered to be the strongest risk factor for Alzheimer’s disease
Amyloid beta may be a symptom of Alzheimer’s — not the cause — and could even have a protective role in the disease process
This means drugs that work by reducing amyloid beta may be missing the problem entirely, putting patients at risk of serious adverse events for little to no benefit

???

Mercola - FDA Accelerated Approval for Risky Lecanemab, reliance on drugs to reduce amyloid beta may be misguided.
FDA Approves Risky FDA Approves Risky Lecanemab